Not applicableUnknownNCT06174857What this trial is testingEfficacy of Osimertinib in Patients With Lung CancerWho this might be right forAdvanced Non-Small Cell Lung Cancer Hunan Province Tumor Hospital 100
Early research (Phase 1)Active Not RecruitingNCT05364073What this trial is testingStudy of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsWho this might be right forNon-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)Looking for participantsNCT07314216What this trial is testingFirmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaWho this might be right forNSCLC (Non-small Cell Lung Carcinoma)Stage IIIEGFR Uncommon Mutations Hunan Cancer Hospital 15
Testing effectiveness (Phase 2)Study completedNCT03434418What this trial is testingA Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsWho this might be right forNon Small Cell Lung Cancer Duke University 17
Testing effectiveness (Phase 2)Study completedNCT04790409What this trial is testingSintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsWho this might be right forLung Cancer Zhejiang Cancer Hospital 21
Large-scale testing (Phase 3)UnknownNCT04951648What this trial is testingA Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR MutationWho this might be right forNon-small Cell Lung Cancer Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Testing effectiveness (Phase 2)UnknownNCT04785742What this trial is testingAlmonertinib for Advanced NSCLC Patients With Rare Mutations in EGFRWho this might be right forSafety of Almonertinib Sun Yat-sen University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06563999What this trial is testingNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Who this might be right forLung Cancer Stage IIIMutation Sun Yat-sen University 120
Large-scale testing (Phase 3)Looking for participantsNCT07010419What this trial is testingAssess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）Who this might be right forNSCLCAdjuvant Treatment Allist Pharmaceuticals, Inc. 338
Testing effectiveness (Phase 2)Looking for participantsNCT06517953What this trial is testingBefotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsWho this might be right forNon-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more Sun Yat-sen University 23
Not applicableUnknownNCT01775943What this trial is testingEfficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLCWho this might be right forLung Neoplasms Ulsan University Hospital 90
Testing effectiveness (Phase 2)UnknownNCT06029816What this trial is testingNeratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsWho this might be right forNSCLC Convalife (Shanghai) Co., Ltd. 42
Testing effectiveness (Phase 2)Ended earlyNCT05215951What this trial is testingOsimertinib Plus Chemotherapy in Uncommon EGFRm NSCLCWho this might be right forLung Cancer AstraZeneca 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167What this trial is testingTesting AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Looking for participantsNCT05967689What this trial is testingZipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.Who this might be right forAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Taiho Oncology, Inc. 220
Testing effectiveness (Phase 2)UnknownNCT02961270What this trial is testingIcotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR MutationWho this might be right forNon-small Cell Lung Cancer Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)UnknownNCT05767866What this trial is testingAssessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFRWho this might be right forTreatmentTreatment Side Effects Suzhou Puhe Pharmaceutical Technology Co., LTD 160
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546866What this trial is testingStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmWho this might be right forNon-small Cell Lung Cancer AstraZeneca 51
Testing effectiveness (Phase 2)Looking for participantsNCT05168566What this trial is testingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Teligene US 99
Testing effectiveness (Phase 2)Active Not RecruitingNCT04504071What this trial is testingDacomitinib in Lung Cancer With Uncommon EGFR MutationsWho this might be right forNon-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer Shanghai Chest Hospital 30